The most common IDH variants in AML and glioma both produce relatively low D-2-HG levels, whilst the most common point mutation in both cholangiocarcinoma and chondrosarcoma produces relatively high levels of the oncometabolite (Table 1) [17,18,19]. The gene discussed is IDH1; the disease is central nervous system cancer.